GAMMAGARD LIQUID - SC Administration
Protecting life’s moments with sustained protection against infection1,2
In the SC administration of GAMMAGARD LIQUID clinical study:
|infection-related hospitalizations per subject per year|
annual rate of acute serious bacterial infections per subject per yeara
days of missed work/school or days unable to perform normal activities per subject per year
- Total number of subject years was 44
aThe upper 99% confidence limit of 0.133 is substantially lower than the minimal goal of achieving a rate of <1 bacterial infection per subject per year.
Subject Discontinuations in the Clinical Study2
- One subject withdrew from the study after 10 treatments with GAMMAGARD LIQUID subcutaneous infusion (2.5 months) due to increased fatigue and malaise
References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-331.